283 related articles for article (PubMed ID: 25746151)
1. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.
Howard K; Hayes A; Cho Y; Cass A; Clarke M; Johnson DW
Am J Kidney Dis; 2015 May; 65(5):773-9. PubMed ID: 25746151
[TBL] [Abstract][Full Text] [Related]
2. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
Perit Dial Int; 2012; 32(5):497-506. PubMed ID: 22991015
[TBL] [Abstract][Full Text] [Related]
3. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
Nephrol Dial Transplant; 2012 Dec; 27(12):4445-53. PubMed ID: 22859794
[TBL] [Abstract][Full Text] [Related]
4. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
5. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
6. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
8. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
9. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi M; Tan SH; Voss D;
J Am Soc Nephrol; 2012 Jun; 23(6):1097-107. PubMed ID: 22440906
[TBL] [Abstract][Full Text] [Related]
10. The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function.
Sikaneta T; Wu G; Abdolell M; Ng A; Mahdavi S; Svendrovski A; Tu T; Mercer T; Tong M; Oreopoulos D; Tam P
Perit Dial Int; 2016 9-10; 36(5):526-32. PubMed ID: 27282852
[TBL] [Abstract][Full Text] [Related]
11. Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial.
Nataatmadja M; Cho Y; Pascoe EM; Darssan D; Hawley CM; Johnson DW;
Perit Dial Int; 2017; 37(4):407-413. PubMed ID: 28408714
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
13. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
14. Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?
Cho Y; Johnson DW
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):192-7. PubMed ID: 24378773
[TBL] [Abstract][Full Text] [Related]
15. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome.
Lee HY; Choi HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Kim MJ; Shin SK
Nephrol Dial Transplant; 2006 Oct; 21(10):2893-9. PubMed ID: 16957012
[TBL] [Abstract][Full Text] [Related]
16. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
17. Associations Between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the
Nataatmadja MS; Johnson DW; Pascoe EM; Darssan D; Hawley CM; Cho Y;
Perit Dial Int; 2018; 38(5):349-355. PubMed ID: 30087174
[TBL] [Abstract][Full Text] [Related]
18. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
Johnson DW; Clarke M; Wilson V; Woods F; Brown FG
BMC Nephrol; 2010 Sep; 11():25. PubMed ID: 20843375
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.
Srivastava S; Hildebrand S; Fan SL
Kidney Int; 2011 Nov; 80(9):986-991. PubMed ID: 21814174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
